Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
16 hedge funds and large institutions have $3.39M invested in Biolase, Inc. in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 16 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
43% less funds holding
Funds holding: 28 → 16 (-12)
45% less capital invested
Capital invested by funds: $6.17M → $3.39M (-$2.78M)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$142K |
| 3 |
Morgan Stanley
New York
|
+$120K |
| 4 |
Renaissance Technologies
New York
|
+$86.2K |
| 5 |
BlackRock
New York
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$70K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$35K |
| 3 |
ZF
Zhang Financial
Portage,
Michigan
|
-$24K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$23.6K |
| 5 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WSC
26
Wellington Shields & Co
New York
| – | -$6K | -7 | Closed |
|
|
TSS
27
Two Sigma Securities
New York
| – | -$5K | -6 | Closed |
|
|
HF
28
HRT Financial
New York
| – | -$4K | -5 | Closed |
|
|
KAS
29
Kestra Advisory Services
Austin,
Texas
| – | -$5K | -5 | Closed |
|
|
TFO
30
Tarbox Family Office
Newport Beach,
California
| – | -$3K | -3 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$549 | -1 | Closed |
|
32
Koshinski Asset Management
Decatur,
Illinois
| – | -$1.06K | -1 | Closed |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$549 | +1 | New |
|
BIOL Hedge Fund Activity: Q2 2022 in Review
16 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2022, worth a combined $3.39M — down 45% from $6.17M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BIOL and 4 opened new positions — a net loss of 12 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.55M. The largest seller was Millennium Management, exiting entirely with an estimated $70K sold.
- 16 institutional investors held Biolase, Inc. (BIOL) as of Q2 2022, down from 28 in Q1 2022.
- Funds reported $3.39M of Biolase, Inc. stock for Q2 2022, down 45% quarter-over-quarter.
- 4 funds opened new Biolase, Inc. positions in Q2 2022 and 16 closed out, a net change of -12 holders.
- The largest Biolase, Inc. buyer in Q2 2022 was Armistice Capital, an estimated $3.55M added.
- The largest Biolase, Inc. seller in Q2 2022 was Millennium Management, an estimated $70K sold.
Based on aggregated 13F filings for Q2 2022.